Neocryptotanshinone

Research use only, not for human use.

Neocryptotanshinone inhibits rabbit platelet aggregation induced by arachidonic acid.

Neocryptotanshinone inhibits rabbit platelet aggregation induced by arachidonic acid.

Neocryptotanshinone exhibits anti-inflammatory effect by suppression of NF-κB and iNOS signaling pathways.Neocryptotanshinone (10 μM and 20 μM, 24 h) inhibits LPS-induced iNOS protein expression in RAW264.7 cells.Neocryptotanshinone (20 μM, 24 h) shows no obvious cytotoxic effect towards murine RAW264.7 macrophages. Cell Viability Assay Cell Line:RAW264.7 cells Concentration:5, 10 and 20 μM Incubation Time:24 hours Result:Inhibited LPS-induced cell viability in a dose-dependent manner.Western Blot Analysis Cell Line:RAW264.7 cells Concentration:20 μM Incubation Time:24 hours Result:Inhibited LPS-induced activation of NF-κB pathway and down-regulated LPS-induced expression of p-NF-κB p65, p-IκBα and p-IKKβ.

Neocryptotanshinone causes reversals of decreased pain thresholds induced by MSU treatment after 30, 60, and 120 min S. miltiorrhiza Bunge extract treatment (contains single active components). Animal Model:MSU-induced pain model in male ICR mice (weighing 20-25 g)Dosage:10, 25, 50 or 100 mg/kg Administration:Oral gavage; for 30, 60, 120 min Result:Inhibited inflammatory symptoms and nociceptive behaviors in a dose-dependent manner.

——

Others

Other Targets

——

——

——

109664-02-0

314.4

C19H22O4

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (318.09 mM)

——

——

(-20℃)

With Ice Pack

≥ 2 years